Drug Profile
Interferon beta-1b biosimilar - Biocure Technology
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Biocure Technology
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Multiple-sclerosis in South Korea (SC, Injection)
- 23 Jan 2019 Biocure Technology announces intention to launch interferon beta-1b biosimilar for Multiple sclerosis by 2021
- 23 Jan 2019 Biocure Technology plans a clinical trial for Multiple sclerosis in 2020 (Biocure Technology website, January 2019)